ORG
Samsung Biologics and Baxter Expand Manufacturing Partnership with $223M Deal
Samsung Biologics, Baxter Healthcare, Manufacturing Deal, $223M, Drug Products, 2034
Medical Devices Outshine Rx Drugs at Cannes Lions, Highlighting Shift in Customer Focus
Cannes Lions, Medical Devices, Rx Drugs, Customer Focus, Jury President
AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment
Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease
Amgen’s Blincyto Wins FDA Approval for Expanded Leukemia Use
Blincyto, Amgen, FDA Approval, Leukemia Treatment, Minimal Residual Disease (MRD), Acute Lymphoblastic Leukemia (ALL), Bispecific Antibody
PTC Therapeutics Reports Positive Phase II Huntington’s Disease Data, FDA Lifts Partial Clinical Hold
PTC Therapeutics, Huntington’s disease, Phase II data, FDA, partial clinical hold, PTC518, mutant huntingtin protein, clinical trends, safety, tolerability.
Lilly Expands Legal Efforts Against Compounded Tirzepatide Sellers, Warns of Counterfeit Risks
Eli Lilly, tirzepatide, Mounjaro, Zepbound, compounded drugs, counterfeit products, legal actions, patient safety
Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years
Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry
Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment
Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment
FDA Places Partial Clinical Hold on Zentalis’ Azenosertib Cancer Studies Following Two Sepsis Deaths
Zentalis Pharmaceuticals, azenosertib, FDA, partial clinical hold, cancer studies, sepsis deaths, WEE1 inhibitor, clinical trials, patient safety
Marea Therapeutics Launches with $190M Funding to Combat Adipose Dysfunction
Marea Therapeutics, Adipose Dysfunction, $190M Funding, Biotech, Healthcare